Akebia Therapeutics Investor Relations Material
Latest events
FDA Announcement
Akebia Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Akebia Therapeutics Inc
Access all reports
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product candidate include Vadadustat, an oral therapy for the treatment of anemia due to chronic kidney disease in non-dialysis and dialysis patients; and AKB-9778, which is intended for the treatment of hypoxia-inducible factor stabilization. Its clinical programs also comprise AKB-6548, for the treatment of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis; AKB-5169 for the treatment of pain associated with osteoarthritis; and AKB-6899 for use as a bioavailable prodrug of oxaloacetate to treat disorders accompanied by oxidative stress.
Key slides for Akebia Therapeutics Inc
Investor Presentation
Akebia Therapeutics Inc
Investor Presentation
Akebia Therapeutics Inc
Latest articles
Daniel Ek: Co-founder and CEO of Spotify
Explore Daniel Ek's journey from a tech-savvy teenager to the co-founder and CEO of Spotify and the most influential person in the music industry.
28 Mar 2024
Companies That Had Their IPO in 1992: A Cautiously Optimistic Market
1992 marked a relatively cool IPO landscape and stock market sentiment, in the wake of the early 90s recession.
28 Mar 2024
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Ticker symbol
Country
🇺🇸 United States